Cargando…
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies
Therapeutic monoclonal antibodies for the treatment of cancer came of age in 1997, with the approval of anti-CD20 Rituximab. Since then, a wide variety of antibodies have been developed with many different formats and mechanisms of action. Among these, antibodies blocking immune checkpoint inhibitor...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345008/ https://www.ncbi.nlm.nih.gov/pubmed/32443877 http://dx.doi.org/10.3390/antib9020017 |